Amplitude Surgical Announces H1 2023-2024 Results

€49.1m Sales and €11.8m EBITDA

Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible) (Paris:AMPLI), leading French player on the surgical technology market for lower-limb orthopedics, announces its results for the first half of the 2023-24 financial year.

Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "The Amplitude Surgical Group's sales for the first half of the 2023-24 financial year were up +9.4% at constant exchange rates compared with the first half of the previous year. The increase in sales offset the rise in product cost prices and operating costs, in particular staff costs, resulting in EBITDA growth of +1.5% to €11.8 million. Profit from recurring operations amounted to € 5.1 million, up slightly on the first half of the previous year. The improvement in the financial result leads to a net income close to breakeven for the first half of the 2023-24 financial year."

Financial summary - data at current exchange rates:

In €m - IFRS		H1 2023-24	H1 2022-2023	Change
Sales		49.1	45.2	8.5%
Gross margin		34.7	32.4	7.2%
As % of sales		70.8%	71.6%	-86bp
Sales & marketing expenses		14.8	13.8	7.4%
Administrative expenses		7.3	6.2	17.9%
Research & Development costs		0.8	0.8	5.4%
EBITDA		11.8	11.7	1.5%
As % of sales